TORONTO, March 4, 2019 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), a vertically integrated cannabis leader with core
operations in Latin America,
announced today that the Company will host a Toronto reception on Thursday, March 7 to announce Cannamexico World
Summit 2019, one of the largest and most influential cannabis
conferences in Latin America. The
Toronto reception will introduce
the summit agenda, the first Canadian Pavilion and feature an
exclusive on-stage Q&A with Mr. Vicente
Fox, the 55th President of Mexico, and former CEO of Coca Cola
Mexico.
WHO: Khiron Life Sciences and CentroFox
WHAT: Cannamexico World Summit 2019 Launch
WHERE: | St.Regis Hotel, 325 Bay Street,
Toronto
WHEN: | Thursday March 7, 12:30pm – 2:00pm
This event is for invited guests and media. Luncheon will be
served.
Q&A Highlights: Mr. Fox will discuss opportunities in
Mexico's cannabis industry, offer
an outlook on the global industry and how cannabusinesses can
continue to build ties between Canada, Mexico and across Latin America. The on-stage Q&A with Mr.
Fox will be available on livestream at
https://www.meetview.com/khiron20190307/
The Cannamexico World Summit 2019, taking place April 25-26 in Guanajuato, Mexico, will bring together more
than 2,000 attendees from across the region, connecting the
cannabis community with national and international experts on
priority topics, including; regulatory affairs, eco-growth and
sustainability, medicine and science, pain reduction and industry
growth opportunities. For the first time, Khiron and Cannamexico
will host The Canadian Pavilion, a significant on-site space
dedicated to showcasing Canada's
leading cannabis and related companies engaged in developing
business growth opportunities in Mexico.
Vicente Fox, the 55th
President of Mexico, former CEO of
Coca-Cola Mexico, and founder of CentroFox, stated, "The cannabis
industry has the potential to be a pillar of our economies, and as
legislation progresses across Latin America I invite attendees to
Cannamexico 2019, a global summit that will bring together the
worlds cannabis community to debate responsible and commercially
successful developments in Mexico
and across the region."
Khiron is strategically positioned to enter the Mexican market.
As previously announced, Khiron's Mexico subsidiary has received approval to
commercialize three products from Khiron's nutraceutical product
line, it is set up in the country to submit license applications,
and has initiated an in-depth regulatory review of the
country's legal medical cannabis landscape as well as an assessment
of market needs. The commencement of sales
in Mexico is subject to prior TSX Venture Exchange
("TSXV") approval. Mexico comprises a population of
approximately 124 million people, with nearly 11.7 million
potential patients for medical cannabis.
About Cannamexico
Presented by CentreFox and Khiron Life Sciences, Cannamexico is
a global summit focused on showcasing the potential for the
Cannabis industry in Mexico, a market estimated at
2 Billion USD (Source: Prohibition
Partners). The summit brings together regional and global cannabis
leaders to discuss regulatory developments, market opportunities,
medical advances, innovation, and wellness for the LatAm cannabis
industry.
For more information visit the
website: http://cannamexico.com.mx/en
About Khiron
Khiron Life Sciences Corp. is positioned to be the dominant
integrated medical cannabis company in Latin America. Khiron has core operations in
Latin America and is fully
licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both THC (tetrahydrocannabinol) and CBD (cannabidiol)
medical cannabis. In May 2018, Khiron
listed on the TSX Venture Exchange, becoming the first Colombian
based medical cannabis companies to trade on any exchange
globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at https://investors.khiron.ca/
Cautionary Notes
Market and Industry Data
This press release contains market and industry data and
forecasts that were obtained from third-party sources, industry
publications and publicly available information. Third-party
sources generally state that the information contained therein has
been obtained from sources believed to be reliable, but there can
be no assurance as to the accuracy or completeness of included
information. Although management believes it to be reliable, the
Company has not independently verified any of the data from
third-party sources referred to in this press release, or analyzed
or verified the underlying studies or surveys relied upon or
referred to by such sources, or ascertained the underlying economic
assumptions relied upon by such sources.
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable Canadian securities legislation. All information
contained herein that is not historical in nature may constitute
forward-looking information. Forward-looking statements may be
identified by statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Forward-looking statements herein include, but are not limited to,
statements regarding the final acceptance of the TSXV and the
commencement of sales in Mexico.
Readers are cautioned to not place undue reliance on
forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements.
Khiron undertakes no obligation to comment on analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile at www.sedar.com.
The forward-looking information contained in this press release is
expressly qualified by this cautionary statement and are made as of
the date hereof. Khiron disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking information, whether as a result of
new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE Khiron Life Sciences Corp.